European Conference on Advance Clinical Trials and Research November 22-23, 2022 Amsterdam, Netherlands

Meet Experts & Influencers Face to Face

While not all conferences offer you the opportunity to meet your business idols, your chances are greatly improved when you’re sharing the same space. Sometimes it’s about taking a selfie with someone who’s influenced you or sharing a business idea with someone you admire, or making a connection that can lead to finding your next mentor.

For people to meet you

This is particularly vital once you are searching for collaborators, job ideas, or in some fields you will even be searching for committee members. Conferences are in our own way to urge your name and you calculate there as you start to ascertain yourself in your field of study, particularly if lucky to be invited as a speaker.

To present your ideas and work to others

This is one of the more obvious reasons for attending conferences to present your work. It’s good practice in talking about what you do with a variety of people from similar, related, and/or completely different areas of study. Presenting will make you more confident about the work you do and gives you a new perspective about your work as people may ask questions that make you think about your project differently.

Track 1:  Clinical Trials

Clinical trials are human research studies that aim to evaluate a medical, surgical, or behavioural intervention. They are the primary means by which researchers determine whether a new treatment, such as a new drug, diet, or medical device is safe and effective in humans. A clinical trial is frequently used to determine whether a new treatment is more effective and/or has fewer harmful side effects than the standard treatment. Other clinical trials look for ways to detect a disease early, sometimes before symptoms appear. Others investigate ways to avoid a health problem. A clinical trial may also investigate how to improve the lives of people who have a life-threatening disease or a chronic health problem...

• Drug’s Safety and Efficacy
• Pre Clinical Research
• Clinical Study Designs

Track 2:  Patient Centric Clinical Trials

Patients require an ethical and long-term relationship, which reflects in how medications are developed and not considering patients as disposable commodities, but as an integral and valuable collaborator in the process. Second, patients expect to be respected for who they are and what they have to say. Many of the barriers to accessing reliable medical information have been decreased or eliminated. Physicians and pharmaceutical corporations no longer have exclusive access to knowledge about diseases and medical problems, allowing even patients with the highest regard for their doctors to complement physician-provided information with their own layman's research.

• Clinical Development
• Research and Discovery
• Open Communication Channels

Track 3: Adaptive Trial Model

An adaptive clinical trial is a clinical trial that examines a medical equipment or treatment by evaluating potentially other measures, such as side effects, on a predetermined schedule and then modifying the trial protocol parameters in response to those observations. The adaption process, in general, continues throughout the trial as specified in the protocol. There are modifications to the dosage, sample size, medicine being tested, and patient selection criteria. As additional information becomes available, trials become an ongoing process that includes new medicines and patient groups. Before the trial begins, the trial protocol is established, and the protocol describes the adaption timeline and methods..

• Estimating treatment effects
• Trial planning
• Maintaining trial conduct and integrity

Track 4: Post-Clinical Trial closed communities

Clinical trials are essential for developing newer and better treatments to benefit humanity. It is the most costly and time-consuming step in the development of a new medicine. Currently, the scientific period and research are making significant progress in all fields, and more and better pharmaceuticals are being developed to address disorders that are tough to treat. Clinical trials are supervised by a set of well-defined rules that must be followed, but they are nonetheless viewed as a humanitarian concern at times. Because patients are at the centre of every clinical research project, all clinical research guidelines are geared on safeguarding the rights, following the rules, and ensuring the safety and well-being of study participants.

• Post trial access
• Drug Marketing
• Clinical Trial Diversity

Track 5: Clinical Data Strategy and Analytics

Only large firms can afford a complete data strategy, which is necessary for building a regulated data flow and prioritising strategy. Data strategy aids in the organization's emphasis on the most pressing issues, ensuring that end users receive value fast. The issues and data confusion that arise with having several CROs and data source suppliers were shared by ECS clients as a software technology enabled data services provider. A structured data strategy can assist firms overcome these obstacles by allowing them to acquire control of the data in which they have invested so much.

• Clinical Data Management
• Automation
• Analytics

Track 6: Clinical Trial Auditing

Independent and methodological review of clinical research activities and documents to determine whether activities related to the establishment and monitoring of this clinical research were carried out, and if data was collected, analysed, and reported in accordance with the protocol and standardised operating procedures. System audits should be small enough to be manageable given the resources available (can be managed). Audits must be planned and carried out in a way that produces acceptable results. Most crucial, do not decrease your audit programme; instead, provide time for unscheduled audits.

• Pre-study Qualification Visit
• Monitoring of Clinical Trials
• Auditing of Clinical Trials

Track 7: Implementing Risk Based Monitoring

Clinical trial costs and complexity have risen considerably in recent years. The conventional on-site evaluation of trial data accounts for one-third of the study's expense. This method, which relies primarily on comprehensive source data verification, has shown to be both resource-intensive and restricted in its capacity to detect and avoid problems. It is widely acknowledged that the procedure for clinical trial monitoring needs to alter in order to ensure the well-being of trial participants and retain the integrity of final results.

• Data Integrity
• Detection of Critical Data and Processes
• Risk Assessment

Track 8: Oncology Clinical Research

Oncology research has a wide range of applications, and clinical trial and study designs are becoming increasingly sophisticated. According to current reports, the success rate of investigational compounds approved for clinical usage in cancer is the lowest of all disorders, with only 6.7 percent of oncology treatments examined in Phase I trials receiving approval. Clinical trials in oncology have a wide range of outcomes. Understanding the distinctions can help enhance both the impact of cancer research on clinical practise and the efficient use of limited resources.

• Cancer subtypes
• Creation of oncology study data
• Systematic evaluation

Track 9: Imaging Research

Medical imaging is the technique of creating images of bodily components for medical purposes such as detecting or studying diseases. Every week, millions of imaging procedures are performed all over the world. Medical imaging is rapidly evolving as image processing techniques such as picture recognition, analysis, and enhancement advance. Image processing improves the percentage of tissues identified as well as the number of tissues detected. The use of image analysis techniques in this subject describes how to solve image interpretation problems with various image processing algorithms as k-means, ROI-based segmentation, and watershed techniques.

• Digital Image Processing
• Medical Imaging Systems
• Image Processing Techniques

Track 10: Post Marketing Surveillance

The science of pharmacovigilance includes post-market surveillance, which involves monitoring the safety of a pharmaceutical medicine or medical device after it has been released on the market. Since drugs and medical devices are accepted and approved based on clinical trials, which involve relatively small numbers of people who do not normally have other medical conditions that exist in the general population, post-marketing surveillance can refine or confirm the safety of a drug or device after it has been used in the general population by large numbers of people with a variety of medical conditions.

• Pharmacovigilance
• Marketing Authorization
• Strategy and Drug Research

Track 11: Pharmacovigilance

Medicines and vaccines have revolutionised disease prevention and treatment. Medicinal products, in addition to their benefits, may have side effects, some of which may be undesirable and/or unexpected. Pharmacovigilance is the science and activities concerned with the detection, assessment, comprehension, and prevention of adverse effects or other medicine/vaccine-related issues.

Before they are approved for use, all medicines and vaccines are subjected to rigorous testing for safety and efficacy in clinical trials. However, the clinical trial process entails studying these products in a small number of carefully selected individuals over a short period of time. Certain side effects may emerge only after these products have been used by a diverse population, including people with other concurrent diseases, for an extended period of time.

Track 12:Drug Designing

Drug design is a capable method of discovering medications based on biological targets. It's also known as a rational drug graph or a rational style. The drug is almost always a natural little molecule that stimulates or inhibits the function of a biomolecule, such as a supermolecule, resulting in a therapeutic benefit to the patient. In its most basic form, a drug graph is dependent on data from the three-dimensional structure of building block targets. The drug is a natural molecule that, once targeted, will either inhibit or remove the feature of a biomolecule that results in therapeutic benefit. A drug sketch is a unique method of medication determined by organic target.

• Structure based drug design   
• Ligand based drug design

Track 13: Pharmaceutical Organic Chemistry

Nanotechnology is now being used at home to produce prescriptions. Engineering includes the use of materials with basic length scales in the nanometre range that exhibit entirely different properties than micrometre organised materials. Such materials will contain particles, strands, grain sizes, and so on. This session focused on the advances that engineering is making in prescription in areas such as disease aversion, analysis, and treatment, as well as (but not limited to) tranquillize revelation, tissue planning, inserts, sensors, sickness treatment, a but not limited to medicate conveyance, tissue building, transplants, sensors, malignant growth treatment, and toxic.

• Drug Resistances
• Nanomaterials

Track 14: Pharmaceutical Drug Discovery and Nanotechnology

Nanotechnology has currently at home with produce prescription. engineering contains the use of materials with basic length scales within the nanometres estimation that exhibit altogether modified properties associated with micrometer organized materials. Such materials will incorporate particles, strands, grain sizes, so forth. This session featured the movements engineering is creating in prescription in such fields as illness aversion, analysis, and treatment together with (however not restricted to) tranquilize revelation, tissue planning, inserts, sensors, sickness treatment, a nonetheless not affected to medicate conveyance, tissue building, transplants, sensors, malignant growth treatment, and toxic.

• Drug Resistances
•  Nanomaterials

• Famous Scientific Professionals in Pharma and Chemistry

• Personnel (Professors, Associate Professors, Asst. Educators)
• Pharma and Chemistry Colleges and Training Institutes
• Drug and Chemistry Associations and Societies
• Drug Business Entrepreneurs
• Assembling Pharmaceutical items Companies
• Assembling Medical Devices Companies
• Pharma and Chemistry Students
• PhD Scholars, Graduates and Post Graduates
• Chiefs, CEO's of Organizations
• Affiliation, Association presidents and experts
• Honorable laureates in Health Care and Medicine
• Bio instruments Professionals
• Bio-informatics Professionals
• Examination Institutes and individuals
• CRO and DATA the executives Companies
• Information Management Companies

Clinical preliminaries are important for discovering novel treatments for illnesses, as well as better ways to distinguish, assess, and reduce the risk of infection. Clinical preliminary studies can show scientists what works and doesn't work in people that can't be learned in a lab or in animals.

The clinical trial market was valued at USD 39,710.28 million in 2021, and it is predicted to grow at a CAGR of 5.05 percent to USD 52,711.08 million by 2027.

The rising need for clinical trials in growing economies, higher R&D spending in the pharmaceutical sector, an increasing prevalence of disorders, and a focus on rare diseases and several orphan medications in the pipeline are all driving the market's growth..

The COVID-19 pandemic has had a significant impact on the clinical trial market, with a growing focus on generating novel treatments or vaccinations to prevent or treat the disease. COVID-19 has also resulted in a minor alteration in the way clinical trials are conducted. In the clinical trial area, there has been a surge in interest in virtual/decentralized trials, which have long been featured on conference agendas and in magazine articles. Despite this, most businesses continue to use the same procedures. COVID-19, on the other hand, has caused some trials to switch to a virtual model in order to stay on schedule during the epidemic.

Due to developments in healthcare and patented novel chemical entities (NCEs) suggested for various health issues, the market is expanding rapidly. Government programmes have also encouraged small, medium, and big companies to enter the drug development business. As a result, a number of medications are in the works. As a result, companies such as Novartis, GlaxoSmithKline, and Pfizer have entered the market. Clinical trials have made more progress in emerging Asia-Pacific and Middle Eastern countries, but there is still a lot of room for growth.